Skip to content
Open access

Human epidermal growth factor receptor 2-low is not a distinct subgroup in breast cancer patients undergoing neoadjuvant chemotherapy

2026 · Mastology · 0 citations

Abstract

Introduction: Breast cancer is a heterogeneous disease, and patients with low expression of human epidermal growth factor receptor 2 (HER2) benefit from antibody-drug conjugate therapies. Objective: To investigate the association between HER2-low status and survival and pathologic complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy. Methods: Prospectively collected data were analyzed from 2010 to 2021 for a total of 544 patients with locally advanced breast cancer subjected to neoadjuvant chemotherapy. HER2 expression was determined by immunohistochemistry and in situ hybridization, and HER2-low was defined as an immunohistochemistry score of 1+ or 2+ and non-amplified in situ hybridization. Kaplan–Meier methods and Cox regression models were used for survival analyses, and logistic regression for pCR. Results: The study identified 78 HER2-low/hormone receptor (HR)–, 90 HER2-low/HR+, 76 HER2+/HR+, 74 HER2+/HR–, 92 luminal, and 134 triple-negative breast cancers (TNBC). Overall survival was strongly associated with hormone receptor (HR) status (hazard ratio [HR] 0.5; 95% confidence interval [CI] 0.3–0.8) and clinical stage (HR 2.4; 95%CI 1.6–3.6), independent of HER2-low status. Consequently, patients were stratified into subgroups according to HR: ER+ group (HER2-low/HR+, HER2+/HR+ and luminal) and ER- group (HER2-low/HR–, HER2+/HR– and TNBC). HER2+ patients achieved the highest pCR rate (52.7% in ER- group [p<0.001] and 33% in ER+ group [p<0.001]). HER2-low/HR+ and HER2-low/HR- patients achieved similar pCR rates (6.7% and 30.8%, respectively) compared to luminal tumors (8.7%; p= 0.80) and TNBC (25.4%; p=0.50), respectively. The prognosis of HER2-low tumors was similar to that of luminal or HER2+/HR+ tumors (HR 1.2; 95%CI 0.6–2.3 and HR 2.3; 95%CI 0.8–6.3), and TNBC or HER2+/HR- (HR 0.9; 95%CI 0.6–1.5 and HR 0.8; 95%CI 0.2–3.4), respectively. Conclusion: HER2-low does not define an independent predictive and prognostic subgroup.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.